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Abstract
We reviewed 355 nerve biopsies analysed at the
Laboratories of Neuropathology of the Born-Bunge
Foundation/University of Antwerp (BBF/UIA) and
University of Liège (ULg) between 1987 and 1997. We
examined the indications for nerve biopsy, the yield of
the procedure, and the influence of clinical and neu-
ropathological parameters. Contributory biopsies
accounted for 35.5% and 47.3% respectively at ULg and
BBF/UIA laboratories : of these, one third showed spe-
cific histological findings, the majority being informa-
tive only when combined with the relevant clinical data.
The profile of indications for nerve biopsy was roughly
comparable in both laboratories. The search for an
inflammatory neuropathy prompted 35-40% of all biop-
sies with more than 50% of specimens being informative
in this indication. The lowest yield (20%) was obtained
among the nerve biopsies performed in the absence of
any presumptive aetiology. These accounted for 22-33%
of all cases. Inadequate surgical resection, delays in
transport or processing errors precluded histological
study of 4% (BBF/UIA) to 8% (ULg) of the specimens.
We conclude that nerve biopsies should be performed by
experienced surgeons and handled in specialised labo-
ratories. Only a relatively small number of causes of
neuropathy can be diagnosed on the basis of histology
alone. More often, contributory biopsies will result from
the combination of non-specific suggestive histological
features with relevant clinical information. The diagnos-
tic yield of nerve biopsy is function of careful patient
selection and close collaboration between the clinician
and the neuropathologist.
Key words : Neuropathy ; nerve biopsy ; CIDP ; indica-
tion ; vasculitis.
Introduction
Peripheral neuropathy is a common disease in
the Western world. Recent surveys from Italy and
France have estimated the prevalence of peripheral
neuropathy at 3.4-3.5% in the elderly (Hessel et al.,
1986 ; The Italian General Practitioner Study
Group (IGPSG), 1995, while the incidence of poly-
neuropathy in the USA is 40/100.000 (Kurtzke,
1982). In a majority of cases, the neuropathy only
results in minor discomfort such as limited pares-
thesia or hypoesthesia, or occasional muscle
cramps, and patients do not seek further medical
attention. In these cases, the aetiology is most often
metabolic, toxic or nutritional with diabetes melli-
tus and alcoholism as predominant causes
(IGPSG, 1995). However, in a subset of patients,
peripheral neuropathy manifests as a disabling
and/or painful condition motivating neurological
consultation. In selected series from hospitals,
metabolic, toxic and nutritional causes still repre-
sent 50% of aetiologies. Other causes include :
inflammatory neuropathy (10-20%), inherited dis-
ease (10-20%), and associated neoplasm (5-10%)
(Hessel et al., 1986 ; Bouche et al., 1992 and
1998).
It is generally admitted that in 10-20% of cases,
no aetiology is found despite extensive investiga-
tion (McLeod et al., 1984 ; Vallat et al., 1984 ;
Argov et al., 1989 ; Corvoisier et al., 1987 ;
Graham et al., 1991). Among these patients with
cryptogenic neuropathy, those who are affected by
a disabling and/or painful disease of recent onset or
progression are potential candidates for a nerve
biopsy. For any patient, the decision to undertake a
nerve biopsy will have to weigh the potential bene-
fit of histological examination and the possibility
of subsequent treatment or genetic counselling
against the post-operative sequelae. As there is no
international consensus on the indications for nerve
biopsy, clinicians often have to rely on the various
and sometimes discordant guidelines published in
the recent literature (Oh 1990 ; Dyck et al., 1992
and 1996 ; Rappaport et al., 1993 ; Midroni and
Bilbao, 1995b ; Chia et al., 1996 ; Bouche et al.,
1998 ; Schröder, 1998).
Reviewing the collections of nerve biopsies
analysed at the laboratories of neuropathology of
Born-Bunge Foundation/University of Antwerp
(BBF/UIA) and University of Liège (ULg) be-
tween 1987 and 1997, we selected 355 nerve
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biopsies from patients over 12 years of age with
sufficient clinical information to determine : a) the
indications for nerve biopsy, b) the yield of the pro-
cedure, and the influence of clinical and neu-
ropathological parameters (Deprez et al., 2000).
Indications to the nerve biopsy
The annual number of nerve biopsies analysed at
the laboratories of ULg and BBF/UIA has gradual-
ly increased between 1987 and 1998 as shown in
Figure 1. This may seem unexpected given the con-
tinuous development of alternative procedures for
the diagnosis of neuropathies. This is particularly
true for hereditary conditions such as hereditary
motor and sensory neuropathies (HMSN), heredi-
tary neuropathy with liability to pressure palsies
(HNPP) and various metabolic inherited diseases
for which molecular genetic analysis of lympho-
cytes, biochemical screening and alternative sites
of biopsy are now the procedures of choice
(Bouche et al., 1992 ; McCarthy et al ., 1995 ;
Midroni and Bilbao, 1995b ; Martin et al., 1996 ;
Ceuterick-de Groote et al., 1998 ; Schröder, 1998).
The profile of indications for nerve biopsy,
roughly comparable in both laboratories during the
period studied, provides some insights into the
causes of the increased use of this procedure
(Table 1, columns 1, 2 and 3).
a) The most frequent indication was the absence
of any presumptive aetiology at the time of biopsy
(22-33% of cases). This loosely refers to the cate-
gory of cryptogenic neuropathies although this
term obviously encompasses different subgroups
according to the extent of pre-operative investiga-
tion (Matthews, 1952 ; Dyck et al., 1981 ; Fagius,
1983 ; McLeod et al., 1984 ; Vallat et al., 1984 ;
Hessel et al., 1986 ; Corvoisier et al., 1987 ;
Graham et al., 1991 ; Notermans et al., 1993). In
this study, 67% of the patients included in this cate-
gory had clinical and electrophysiological charac-
teristics similar to those described in previous
studies on cryptogenic neuropathy : a mean age of
62 years, sensory or sensory-motor polyneuro-
pathy, with a distal and symmetric topography, and
electrophysiological findings of predominantly
axonal neuropathy (Matthews, 1952 ; Dyck et al.,
1981 ; Fagius, 1983 ; Asbury and Gilliatt, 1984 ;
McLeod et al., 1984 ; Corvoisier et al., 1987 ;
Graham et al., 1991 ; Bouche et al., 1992 ;
Notermans et al., 1993). 
b) Biopsies undertaken for suspected vasculitis
and suspected chronic inflammatory demyelinating
polyneuropathy (CIDP) each accounted for about
10% of cases. Moreover, the search for an inflam-
matory neuropathy was often also part of the dif-
ferential diagnosis in those patients with multiple
potential causes, raising the total frequency to 35-
40% of all biopsies analysed. These rather high fig-
ures may indicate an increasing clinical awareness
of the wide spectrum of presentations of these
potentially treatable inflammatory neuropathies
(Vincent et al., 1985 ; Harati and Niakan, 1986,
Dyck et al., 1987 ; Said et al., 1988 ; Barohn et al.,
1989 ; Hawke et al., 1991 ; Azulay et al., 1992 ;
Kissel and Mendell, 1992 ; Serratrice et al., 1994 ;
Smalland Lovelace, 1994 ; Midroni and Bilbao,
1995c ; Deprez et al, 2000). Accordingly, the bene-
fits of combined muscle and nerve biopsy have
been shown in the diagnosis of vasculitis affecting
the peripheral nervous system (PNS). However, it
should be emphasised that the value of microscop-
ic examination for the diagnosis of CIDP is still a
matter of debate due to the lack of specificity of
most associated histological findings (Barohn et
al., 1989 ; Krendel et al., 1989 ; Gabreels-Festen et
al., 1993 ; Small and Lovelace 1994 ; Midroni and
Bilbao, 1995b). 
c) Clinical suspicion of HMSN motivated 13-
15% of the biopsies with 65% of these having been
performed before 1992. In the earlier years of the
study, a large number of biopsies were performed
in suspected HMSN I and HNPP and they often
brought contributory information. They were pro-
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Table 1
Nerve biopsy : indications and yield (N = 355)
Indication Frequency Contributory biopsies
BBF ULg BBF ULg
No working Diagnosis 33% 22% 21% 18%
Suspected CIDP 12% 12% 64% 47%
Suspected vasculitis 13% 6% 50% 66%
Multiple potential causes 15% 20% 42% 19%
HMSN 15% 13% 79% 71%
Other metabolic diseases 7% 11% 22% 37%
Substantiate PNP 5% 16% * *
BBF : Laboratory of Neuropathology of the Born Bunge Foundation and University of Antwerp.  ULg : Laboratory of neuro-
pathology of the University of Liege. CIDP : Chronic Inflammatory Demyelinating Polyneuropathy.  PNP : Polyneuropathy. HMSN :
Hereditary Motor and Sensory Neuropathy. 
* This category was not included in the evaluation of the yield of the nerve biopsy because the type of answer  “yes or no” corres-
ponds to a 100% yield. 
gressively replaced by the less invasive techniques
of molecular genetics. Later biopsies were prompt-
ed by discordance between clinical and genetic
data in cases of HMSN I, or suspected HMSN II
and V. In HMSN II, however, histological changes
are rather non-specific as they show a predomi-
nantly axonal neuropathy with large diameter fibre
attrition, numerous regenerative clusters and occa-
sional small onion bulbs. 
d) There were significant differences between
the two laboratories with respect to the proportion
of nerve biopsies performed to substantiate a neu-
ropathic process, with 16% and 5% of cases
respectively at ULg and BBF/UIA. This category
encompassed a) cases with discordance between
the patient’s complaint and clinical and/or electro-
physiological findings, b) a differential diagnosis
between amyotrophic lateral sclerosis (ALS) and
genuine polyneuropathy, and rarely, c) between
neuropathy and myopathy.
Contribution of nerve biopsy
to the final diagnosis
To evaluate the yield of nerve biopsies, we
referred to the criteria published by Midroni et al.
(Midroni and Bilbao, 1995b) and Argov et al
(Argov et al., 1989). Contributory biopsies provid-
ed information that was either essential or helpful
for the patient’s management. Essential biopsies
showed abnormalities specific or highly suggestive
of a definitive diagnosis. Helpful biopsies showed
non specific histological changes that proved con-
tributory when related to the clinical data, either by
supporting or ruling out a working diagnosis, or by
distinguishing among several potential causes, or
by showing the presence of inflammatory infil-
trates (Deprez et al., 2000). Non contributory biop-
sies did not influence patient’s management other
than providing an impression of the severity and
activity of the disease. 
In our study, contributory biopsies accounted for
35.5% and 47.3% respectively at ULg and
BBF/UIA laboratories. These results are roughly
similar to those of other authors using similar
criteria (Argov et al., 1989 ; Midroni and Bilbao,
1995b ; Chia et al., 1996). Of these biopsies, spe-
cific or highly suggestive findings were present in
only one third, emphasising the need for a close
collaboration between clinicians and neuropatho-
logists. 
Inadequate surgical resection, delays in transport
or processing errors precluded histological study of
4% (BBF/UIA) to 8% (ULg) of the specimens.
Given the propensity of nerve tissue to mechanical
and chemical damage, nerve biopsies should
always be performed by experienced surgeons and
handled in specialised laboratories. The unaccept-
able figures of specimen loss in this study confirm
previous authors’ emphasis on the importance of
following a specific protocol for nerve biopsy
(Dyck et al., 1993 ; Midroni and Bilbao, 1995a ;
Bouche et al., 1998 ; Schröder, 1998).
The lowest yield (20%) for nerve biopsy was
obtained from patients referred without working
diagnosis (table 1). Although in all previously pub-
lished series, a definite subset of polyneuropathies
remain cryptogenic, clinicians should attempt to
reduce the proportion of patients in this category by
conducting extensive preoperative investigations
and repeated examinations. Indeed, several studies
have shown that in up to one third of reportedly
cryptogenic PNP, long term follow-up would reveal
the aetiology by demonstrating a toxic cause or an
hereditary condition, or with the emergence of an
underlying systemic disease (Dyck et al., 1981 ;
McLeod et al., 1984 ; Corvoisier et al., 1987 ;
Graham et al., 1991). However, in this study, 9/21
(43%) contributory biopsies demonstrated an unex-
pected CIDP (7), or microvasculitis (2), con-
fronting the clinicians with the difficult issue of the
best timing for nerve biopsy.
The high yield of nerve biopsy associated with
hereditary conditions such HMSN has already been
discussed above in its historical perspective. 
This study also includes information relevant to
the diagnosis of inflammatory neuropathies. Nerve
biopsies performed in the context of suspected vas-
culitis were contributory in 50% (BBF/UIA) and
66% (ULg) of cases. Previous studies have shown
that the sensitivity of the nerve biopsy in this indi-
cation is increased by 15-40% when combined with
a muscle biopsy (Vincent et al., 1985 ; Harati and
Niakan, 1986 ; Dyck et al., 1987 ; Said et al.,
1988). The high yield obtained at ULg for this
indication probably reflects the more frequent use
of combined nerve-muscle biopsies (Deprez et al.,
2000). It is of interest that, in the 18 cases of histo-
logically proven microvasculitis included in our
study, only 44% presented with mononeuritis mul-
tiplex, the remaining showing symmetrical (33%)
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FIG. 1. — Number of nerve biopsies examined at the labo-
ratories of ULg and BBF/UIA between 01/01/1987 and
31/12/1998.
or asymmetrical (22%) distal polyneuropathy.
While the onset was acute or subacute in a majori-
ty of case, 4 patients presented with a chronic slow-
ly progressive or relapsing neuropathy. Only 28%
had manifestations of a systemic disease at the time
of biopsy ; biological evidence of an inflammatory
syndrome was present in 70%. 
The benefit of nerve biopsy in cases with sus-
pected CIDP is a matter of debate. In our study,
47% (ULg) and 64% (BBF/UIA) of biopsies were
contributory, most often supporting the preopera-
tive diagnosis. This rather high yield may be inflat-
ed by our evaluation criteria. Highly suggestive his-
tological findings such as the association of onion
bulbs, ongoing demyelination and endoneurial
inflammatory infiltrates were seen in only 22% of
the contributory biopsies, while only one nerve
showed the characteristic ultrastructural finding of
macrophage-mediated myelin stripping. This low
sensitivity has also been reported by previous
authors (Barohn et al., 1989 ; Krendel et al., 1989 ;
Gabreels-Festen et al., 1993 ; Small and Lovelace,
1994 ; Midroni and Bilbao, 1995b ; Molenaar et
al., 1998). In the 78% remaining cases, helpful
findings were the observation of inflammatory
infiltrates in an otherwise established demyelinat-
ing neuropathy or the finding of onion bulbs and
prominent ongoing demyelination in a previously
reported axonal neuropathy. In three cases the diag-
nosis of CIDP was ruled out by the histological
findings of tomacular neuropathy, later genetically
confirmed as HNPP, and in one case, by orientating
the diagnosis towards a diabetic neuropathy.
The 24 cases of CIDP included in this study also
confirmed the wide clinical spectrum of this condi-
tion : 50% of patients presented clinically with a
chronic distal symmetrical polyneuropathy ; elec-
trophysiological studies supported a predominantly
axonal process in 9/24 cases ; 8/24 cases had a nor-
mal CSF protein content. 
Although our figures parallel those reported by
previous authors using similar criteria, a more
extensive survey of the previous literature shows
considerable variation in the yield of nerve biopsy
reported by various laboratories of Neuropathology
(Argov et al., 1989 ; Neundorfer et al., 1990 ; Oh,
1990 ; Rappaport et al., 1993 ; Midroni and Bilbao,
1995b ; Chia et al., 1996). When reviewing such
data, caution should be exerted to potential bias
related to clinical and neuropathological parame-
ters of selection (Deprez et al., 2000). 
Conclusions
For any patient, the decision to perform a nerve
biopsy should take into consideration :
1. The extent of pre-biopsy investigations, includ-
ing repeated clinical and electrophysiological
examination
2. The specificity and sensitivity of nerve biopsy
according to the suspected aetiology
3. The availability of therapy and/or genetic coun-
selling
4. Post-operative sequelae.
Nerve biopsies should be performed by experi-
enced surgeons and handled in specialised labora-
tories. Only a relatively small number of causes of
neuropathy can be diagnosed on the basis of histol-
ogy alone. More often, contributory biopsies will
result from the combination of non-specific sug-
gestive histological features with relevant clinical
information. The diagnostic yield of nerve biopsy
is function of careful patient selection and close
collaboration between the clinician and the neu-
ropathologist. It is hoped that new diagnostic tools
generated from in vitro and animal models will
increase the diagnostic yield of peripheral nerve
biopsy.
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